EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma

Mylan R Blomquist, Ryan Eghlimi, Angad Beniwal, Dustin Grief, David G Nascari, Landon Inge, Christopher P Sereduk, Serdar Tuncali, Alison Roos, Hannah Inforzato, Ritin Sharma iD, Patrick Pirrotte und 4 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25116279 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Mylan R Blomquist und 15 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Alix School of Medicine, Mayo Clinic Arizona, Phoenix, AZ 85054, USA. Hauptthemen laut MEDLINE: STAT5 Transcription Factor, Glioblastoma, Quinazolines, Benzodioxoles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with few effective treatments. EGFR alterations, including expression of the truncated variant EGFRvIII, are among the most frequent genomic changes in these tumors. EGFRvIII is known to preferentially signal through STAT5 for oncogenic activation in GBM, yet targeting EGFRvIII has yielded limited clinical success to date. In this study, we employed patient-derived xenograft (PDX) models expressing EGFRvIII to determine the key points of therapeutic vulnerability within the EGFRvIII-STAT5 signaling axis in GBM. Our findings reveal that exogenous expression of paralogs STAT5A and STAT5B augments cell proliferation and that inhibition of STAT5 phosphorylation in vivo improves overall survival in combination with temozolomide (TMZ). STAT5 phosphorylation is independent of JAK1 and JAK2 signaling, instead requiring Src family kinase (SFK) activity. Saracatinib, an SFK inhibitor, attenuates phosphorylation of STAT5 and preferentially sensitizes EGFRvIII+ GBM cells to undergo apoptotic cell death relative to wild-type EGFR. Constitutively active STAT5A or STAT5B mitigates saracatinib sensitivity in EGFRvIII+ cells. In vivo, saracatinib treatment decreased survival in mice bearing EGFR WT tumors compared to the control, yet in EGFRvIII+ tumors, treatment with saracatinib in combination with TMZ preferentially improves survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT5 Transcription FactorGlioblastomaQuinazolinesBenzodioxolesErbB ReceptorsTemozolomideCell ProliferationHumansAnimalsMicePhosphorylationCell Line, TumorXenograft Model Antitumor AssaysSignal TransductionBrain NeoplasmsApoptosissrc-Family KinasesTumor Suppressor Proteins

Stichwörter der Autor:innen

cell signalingglioblastomaprecision oncologyreceptor tyrosine kinase

Substanzen

STAT5 Transcription FactorQuinazolinesepidermal growth factor receptor VIIIBenzodioxolesErbB ReceptorssaracatinibSTAT5A protein, humanTemozolomideSTAT5B protein, humansrc-Family Kinases

Autor:innen und Institutionen

  • Mayo Clinic Alix School of Medicine, Mayo Clinic Arizona, Phoenix, AZ 85054, USA.
  • Department of Cancer Biology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA.
  • Ventana Medical Systems, Roche Diagnostics, Tucson, AZ 85755, USA.
  • Collaborative Center for Translational Mass Spectrometry, The Translational Genomics Research Institute, Phoenix, AZ 85004, USA.
  • Department of Translational Neuroscience, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA.
  • Department of Hematology and Oncology, Mayo Clinic Arizona, Phoenix, AZ 85054, USA.

ORCID-Profile: Ritin Sharma, Shannon P Fortin Ensign

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Blomquist, M. R., Eghlimi, R., Beniwal, A., Grief, D., Nascari, D. G., Inge, L., Sereduk, C. P., Tuncali, S., Roos, A., Inforzato, H., Sharma, R., Pirrotte, P., Mehta, S., Fortin Ensign, S. P., Loftus, J. C., & Tran, N. L. (2024). EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25116279

Vancouver

Blomquist MR, Eghlimi R, Beniwal A, Grief D, Nascari DG, Inge L, et al. EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25116279

BibTeX
@article{Blomquist2024,
  author = {Blomquist, Mylan R and Eghlimi, Ryan and Beniwal, Angad and Grief, Dustin and Nascari, David G and Inge, Landon and Sereduk, Christopher P and Tuncali, Serdar and Roos, Alison and Inforzato, Hannah and Sharma, Ritin and Pirrotte, Patrick and Mehta, Shwetal and Fortin Ensign, Shannon P and Loftus, Joseph C and Tran, Nhan L},
  title = {EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25116279}
}
Kostenlos starten →